Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > so given the Disclosure below

<< Previous

Bullboard Posts

Next >>

Comment by m8magicon Dec 30, 2020 12:30am

148 Views

Post# 32195133

RE:RE:so given the Disclosure below

Rumpl3StiltSkin wrote:

m8magic wrote: Does Macfarlane have any research with TLTs team..(i dont find here on their site)...so what is the extent of her monatary rewards with TLTs success...and i assume she is restricted from any wandering from the ties to TLT. The Disclosure below i find extremly positive...wow..thanx again to Eg...he keeps those to keep the faith with good reason...thank you thank you

Disclosure statement

S.A.M. has a potential research conflict of interest due to a financial interest with Theralase Technologies, Inc. and PhotoDynamic, Inc. A management plan has been created to preserve objectivity in research in accordance with UTA policy.

This discovery benefits her Directly via her commpany, and indirectly from TLT, who benefit semi-directly from this find.